New Suit Says Makers of Testosterone Drug AndroGel Hid Risks of Myocardial Infarction, Stroke
February 5, 2014
CHICAGO — A new suit filed in Illinois federal court accuses the makers of AndroGel of hiding serious health risks associated with the testosterone replacement drug, including myocardial infarction, stroke and death.
According to the Feb. 4 complaint filed in the U.S. District Court for the Northern District of Illinois against Abbott Laboratories Inc. and its subsidiary, AbbVie Inc., AndroGel use may increase the incidence of myocardial infarctions and death by more than 500 percent. In addition, AndroGel has been linked to medical disorders in those who come into physical contact with the drug’s users or the unwashed clothes of ...
Associated Law Firms
Morelli Alters Ratner
Simmons Browder Gianaris Angelides & Barnerd